New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on ...

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a ...

The FDA’s real-time clinical trial mechanism allows drug sponsors to transmit data immediately to the regulator through the ...

A quantum tech firm that has collaborated with—and received investment from—Amgen is now planning to go public. | A quantum ...

Earlier this year, when the FDA asked Amgen to pull its rare disease drug Tavneos from the market, the California drugmaker ...

May 4 (Reuters) - Amgen said on Monday it was investing an additional $300 million in Puerto Rico to expand its U.S.

Amgen has pulled the plug on midstage drug candidates for cancer and the autoimmune disease Sjögren’s syndrome, terminating ...

Repatha’s withdrawal from Denmark is best understood as an early signal of the impact of Most Favored Nation drug pricing ...

Viridian Therapeutics unveiled solid results Tuesday for its experimental eye disease treatment, a potential rival to Amgen.

Amgen doubles down in New Albany: expansion plus solar, CO2 refrigeration and EV chargers as it chases carbon neutrality.

Thousand Oaks-based Amgen continues to invest in its onshore capabilities, after the biotech giant announced plans to invest an additional $300 million in its U.S. manufacturing network to further ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...